ライフサイエンスコーパス: gadolinium

1 hantom by using the characteristic k edge of gadolinium.

2 determine the absolute content of iodine and gadolinium.

3 em under acidic conditions is evaluated with Gadolinium- 2,2',2''-(((nitrilotris(ethane-2,1-diyl))tri

4 lective mechano-gated channel inhibitor than gadolinium and a particularly potent inhibitor of mechan

5 PRLR ligand, to magnetic resonance imaging (gadolinium) and near-infrared fluorescence imaging agent

6 Extremely low levels of gadolinium are found in juvenile macaque tissues after i

7 Conclusion Low levels of gadolinium are present in the brain after repeat dosing

8 d agents and may overcome concerns regarding gadolinium-associated toxicity and retention.

9 /dL) at any time point (iodine- [P > .12] or gadolinium-based [P > .13] contrast material).

10 aphy with comparable contrast enhancement to gadolinium-based agents and may overcome concerns regard

11 ted tomography (CT) to differentiate between gadolinium-based and nonionic iodine-based contrast mate

12 live mice by using metabolic labeling and a gadolinium-based bioorthogonal MRI probe.

13 gnetic resonance (MR) images with increasing gadolinium-based contrast agent (GBCA) doses in patients

14 acranial abnormalities following intravenous gadolinium-based contrast agent (GBCA) exposure might be

15 st five serial injections of the macrocyclic gadolinium-based contrast agent (GBCA) gadoterate meglum

16 exposure of the pediatric brain to a linear gadolinium-based contrast agent (GBCA) is associated wit

17 ormal renal and hepatic function who undergo gadolinium-based contrast agent (GBCA)-enhanced magnetic

18 tion following multiple intravenous doses of gadolinium-based contrast agent (GBCA).

19 llergic-like reaction, 28 (34.1%) received a gadolinium-based contrast agent before and had no reacti

20 contrast effects with those of a commercial gadolinium-based contrast agent for their applicability

21 lymphatic vessels enhance with gadobutrol, a gadolinium-based contrast agent with high propensity to

22 2; subjects had never received injections of gadolinium-based contrast agent) examined with a standar

23 applied field strength and administration of gadolinium-based contrast agent.

24 e relationship between the administration of gadolinium-based contrast agents (GBCAs) and gadolinium

25 se procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstr

26 mary brain tumor who had not received linear gadolinium-based contrast agents (GBCAs) but had receive

27 pecies after multiple administrations of the gadolinium-based contrast agents (GBCAs) gadodiamide and

28 r repeated administration of the macrocyclic gadolinium-based contrast agents (GBCAs) gadoteridol and

29 ore than 20 serial injections of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal i

30 Gadolinium-based contrast agents (GBCAs), once believed

31 atients independent of the administration of gadolinium-based contrast agents (GBCAs).

32 immediate allergic events between classes of gadolinium-based contrast agents (GBCAs).

33 es in patients with prior exposure to linear gadolinium-based contrast agents (GBCAs).

34 Cardiovascular magnetic resonance with gadolinium-based contrast agents has established as gold

35 cular mapping without exposure to iodine- or gadolinium-based contrast agents.

36 s of the functional outcome after MI without gadolinium-based contrast agents.

37 ral orders of magnitude higher than those of gadolinium-based contrast agents.

38 of the brain with repeated administration of gadolinium-based contrast agents.

39 dations for the clinical and research use of gadolinium-based contrast agents.

40 Coadministration of gadolinium-based contrast and a CCR2 inhibitor reduced t

41 to administration of intravenous iodine- and gadolinium-based contrast material.

42 ctional role of chemokines in the effects of gadolinium-based contrast was further confirmed in in si

43 temic fibrosis can be induced in humans with gadolinium-based contrast, and cumulative doses correlat

44 Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis.

45 In this system, a gadolinium-based nonionic paramagnetic agent is used in

46 is of particular interest in cases in which gadolinium-based perfusion is contraindicated (eg, aller

47 re we used magnetic resonance imaging with a gadolinium-based probe targeted to type I collagen (EP-3

48 luid absorption was sensitive to ouabain and gadolinium but insensitive to benzamil, bafilomycin and

49 Gadolinium can be retained in bone after one dose of GBC

50 We report herein a novel allysine-binding gadolinium chelate (GdOA), that can non-invasively detec

51 he concordance between (18)F-FDG avidity and gadolinium chelate enhancement.

52 Ultra-small, renal clearable, silica based gadolinium chelated nanoparticles (SiGdNP) provide simul

53 The Gadolinium-chelated HPMA copolymers also showed signific

54 ed delivery of both Evans blue dye (EBD) and Gadolinium-chelated N-(2-hydroxypropyl)methacrylamide (H

55 ts alike are starting to question the use of gadolinium chelates for clinical magnetic resonance (MR)

56 tive KC, recipients were preconditioned with gadolinium chloride.

57 teridol and to quantify the amount of intact gadolinium complexes and insoluble gadolinium-containing

58 and blood normalized initial area under the gadolinium concentration curve to 90 seconds, or IAUGCBN

59 oncentration measured in bone (R(2) = 0.41); gadolinium concentration in bone increased by 0.39 mug G

60 Results Gadolinium concentration in bone was significantly highe

61 Results Gadolinium concentration in the amniotic fluid was 0.028

62 A one-tailed t test was performed to compare gadolinium concentration in the exposed group with that

63 etween the dose of GBCA administered and the gadolinium concentration measured in bone (R(2) = 0.41);

64 etween the dose of GBCA administered and the gadolinium concentration measured in bone was analyzed w

65 wo parts, one for determination of the total gadolinium concentration with inductively coupled plasma

66 e, maximum slope enhancement, area under the gadolinium concentration-time curve during the first 90

67 Results The mean total gadolinium concentrations for gadodiamide and gadoterido

68 be used to calculate the concentration of a gadolinium-containing contrast agent in a region of inte

69 termination of the amount of intact GBCA and gadolinium-containing insoluble species.

70 nium implies the occurrence of other soluble gadolinium-containing species (approximately 30%).

71 Purpose To evaluate the speciation of gadolinium-containing species after multiple administrat

72 dodiamide yielded both soluble and insoluble gadolinium-containing species, with insoluble species do

73 of intact gadolinium complexes and insoluble gadolinium-containing species.

74 eedle injection of caustic agents doped with gadolinium contrast under real-time magnetic resonance i

75 SI in T1 sequences as an indicator of brain gadolinium deposition detectable by using MR imaging.

76 f a noninvasive measurement system to assess gadolinium deposition in bone and to investigate the rel

77 fluorescence system is capable of measuring gadolinium deposition in bone noninvasively in vivo.

78 Results Gadolinium deposition in brain tissue significantly vari

79 Conclusion Gadolinium deposition in neural tissues after GBCA admin

80 ing concerns about nephrogenic sclerosis and gadolinium deposition in the brain, physicians and patie

81 to show adverse clinical effects due to the gadolinium deposition in the brain.

82 Gadolinium deposition in the contrast group was localize

83 irm previous research findings that there is gadolinium deposition in wider distribution throughout t

84 in T1 sequences as a potential indicator of gadolinium deposition increases after repeated administr

85 Purpose To determine if hepatic gadolinium deposition occurs in pediatric patients with

86 However, the extent of gadolinium deposition varies between agents.

87 Similar relative differences in gadolinium deposition were observed in renal, hepatic, a

88 uantify, localize, and assess the effects of gadolinium deposition.

89 Gadolinium deposits have been confirmed in brain tissue,

90 Purpose To determine whether gadolinium deposits in neural tissues of patients with i

91 Gadolinium deposits were visualized directly in the endo

92 y for quantification and characterization of gadolinium deposits.

93 The adsorption of ubiquitin on gadolinium-doped fluoride-based NPs produced residue-spe

94 ween dentate nucleus SI and total cumulative gadolinium dose (r = 0.4; 95% confidence interval [CI]:

95 ween groups and relative to total cumulative gadolinium dose, age, sex, and number of and mean time b

96 ox-driven oxygen migration from NiCoO to the gadolinium, during growth or soon after.

97 All patients underwent contrast (gadolinium)-enhanced MRI.

98 This patient remained asymptomatic, and gadolinium-enhanced (Magnevist; Bayer Pharma, Berlin, Ge

99 interim CVD events; of these, 1723 received gadolinium-enhanced cardiac magnetic resonance for chara

100 utation in SERPINE-1 was evaluated with late gadolinium-enhanced cardiac magnetic resonance imaging.

101 tect such inflammation using high-resolution gadolinium-enhanced contrast scans by the presence of le

102 m five patients who had undergone four to 18 gadolinium-enhanced magnetic resonance (MR) examinations

103 ately 1 cm(3) in volume were visualized with gadolinium-enhanced MR imaging after sonication at an ac

104 ient-specific models reconstructed from late gadolinium-enhanced MRI scans, we simulated channelrhodo

105 The median total number of gadolinium-enhanced T1-weighted lesions from weeks 8 to

106 The primary endpoint was the total number of gadolinium-enhanced T1-weighted lesions on monthly brain

107 mg significantly reduced the total number of gadolinium-enhanced T1-weighted lesions.

108 onography (US) versus that with preoperative gadolinium-enhanced T1-weighted magnetic resonance (MR)

109 scans to corresponding coplanar preoperative gadolinium-enhanced T1-weighted MR images in all cases,

110 Contrast enhancement of gadolinium-enhanced T1-weighted MR imaging and contrast-

111 ent of the entire bulk of the tumor, whereas gadolinium-enhanced T1-weighted MR imaging demonstrated

112 lar distribution in contrast-enhanced US and gadolinium-enhanced T1-weighted MR imaging in nine Seven

113 imposable on that provided with preoperative gadolinium-enhanced T1-weighted MR imaging regarding loc

114 ions, and pattern) was compared with that at gadolinium-enhanced T1-weighted MR imaging.

115 Using gadolinium-enhanced T1-weighted MRI, we determined that

116 higher baseline hs-cTnT categories and late gadolinium enhancement (>/=7.42 ng/L versus <limit of de

117 ger than the infarct size quantified by late gadolinium enhancement (37.2+/-11.6% versus 22.3+/-11.7%

118 The presence of late gadolinium enhancement (65% versus 64%; P=0.99) and the

119 rization, electric markers of scar, and late gadolinium enhancement (all P<0.001).

120 Patients with late gadolinium enhancement (LGE) and low lateral MAPSE had s

121 Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapping, is emerging

122 ameters at diagnosis predict dynamic of late gadolinium enhancement (LGE) as persistent LGE has been

123 ce of ventricular fatty replacement and late gadolinium enhancement (LGE) at cardiac magnetic resonan

124 Late gadolinium enhancement (LGE) border zone on cardiac magn

125 We investigated whether late gadolinium enhancement (LGE) cardiovascular magnetic res

126 Late gadolinium enhancement (LGE) cardiovascular magnetic res

127 levation myocardial infarction (STEMI), late gadolinium enhancement (LGE) has been demonstrated to ov

128 of cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) has not been clarified in a

129 have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogeneity on magnetic r

130 Late gadolinium enhancement (LGE) imaging overestimates acute

131 Myocardial fibrosis was detected by late gadolinium enhancement (LGE) MRI, and myocardial perfusi

132 isolated LV subepicardial/midmyocardial late gadolinium enhancement (LGE) on contrast-enhanced cardia

133 ted myocarditis underwent CMR including late gadolinium enhancement (LGE) parameters between 2002 and

134 dial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their risk of

135 of 1,228 patients with AF who underwent late gadolinium enhancement (LGE)-cardiac magnetic resonance

136 with clinical cardiovascular disease or late gadolinium enhancement (n = 167), and after replacing LV

137 associated with increased occurrence of late gadolinium enhancement (P=0.004).

138 ge transmural (volume of enhancement on late gadolinium enhancement [LGE] images >20%, n = 72) or sma

139 ft ventricular function, and myocardial late gadolinium enhancement [LGE]), and metabolic parameters

140 ascular magnetic resonance imaging with late gadolinium enhancement and a 24-hour Holter.

141 Both transmural extent of late gadolinium enhancement and FDG uptake on the acute scan

142 s regarding the presence of abnormal orbital gadolinium enhancement and judged them as "definitive tu

143 All animals underwent MRI (late gadolinium enhancement and T2-weighted edema imaging) im

144 gher troponin T peak (P<0.0001), larger late gadolinium enhancement area (P<0.0001), and lower left v

145 r troponin T peak (P=0.006) but similar late gadolinium enhancement area (P=0.24) compared with those

146 ing the first trimester of pregnancy or with gadolinium enhancement at any time of pregnancy is unkno

147 tive/postcontrast T1 maps, T2 maps, and late gadolinium enhancement at days 1 and 21 post-MI.

148 The presence of late gadolinium enhancement at magnetic resonance imaging, a

149 electrophysiology mapping) and advanced late gadolinium enhancement cardiac magnetic resonance scar i

150 patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance

151 Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic resonance

152 The edema volume in late gadolinium enhancement correlated well with edema volume

153 Dorsal cord subpial gadolinium enhancement extending >/=2 vertebral segments

154 nstrated that (18)F-FDG extent exceeded late gadolinium enhancement extent (33.2+/-16.2% left ventric

155 Extracellular volume for diffuse and late gadolinium enhancement for focal fibrosis were assessed.

156 Late gadolinium enhancement for replacement fibrosis was dete

157 crovascular obstruction region on acute late gadolinium enhancement images acquired 26.1 minutes afte

158 Late gadolinium enhancement imaging is an established method

159 Quantification of fibrosis from late gadolinium enhancement imaging was incrementally perform

160 etic resonance imaging was positive for late gadolinium enhancement in 21 of 23 (91%) patients, where

161 One subject in group 2 had late gadolinium enhancement in a noncoronary distribution, an

162 le for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and noninvasiv

163 cardiac magnetic resonance imaging with late gadolinium enhancement in phenotyping the left ventricul

164 CMR at 1.5 T including cine, DENSE, and late gadolinium enhancement in subjects >45 years.

165 in early disease stages and complements late gadolinium enhancement in visualization of the regional

166 T2-weighted, native T1/T2 mapping, and late gadolinium enhancement MR imaging.

167 erize different areas of enhancement in late gadolinium enhancement MRI done immediately after ablati

168 Most of these patients were late gadolinium enhancement negative.

169 iRNAs were also decreased in patients with a gadolinium enhancement on brain magnetic resonance imagi

170 years) arrhythmic MVP patients with LV late gadolinium enhancement on cardiac magnetic resonance and

171 fraction was 51% (+/-17%), and 32% had late gadolinium enhancement on cardiac magnetic resonance.

172 letes but none of the controls revealed late gadolinium enhancement on cardiovascular magnetic resona

173 Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic resona

174 ere required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MR

175 Diabetics without late gadolinium enhancement or inducible ischemia had a low a

176 as mainly asymmetrical, and had similar late gadolinium enhancement patterns.

177 In those undergoing CA, the absence of late gadolinium enhancement predicted greater improvements in

178 , 1.6+/-0.3 versus 1.4+/-0.3; P=0.046; early gadolinium enhancement ratio, 3.1+/-1.2 versus 2.1+/-0.6

179 ological abnormalities colocalized with late gadolinium enhancement scar, indicating a relationship w

180 ntal comparison of (18)F-FDG-uptake and late gadolinium enhancement showed substantial overlap (kappa

181 0.016) were higher in MVP patients with late gadolinium enhancement than in those without.

182 was in good agreement with the 6-month late gadolinium enhancement volume (r=0.99) and correlated st

183 In addition, late gadolinium enhancement was also assessed.

184 l LS and CS 2DST and 2DTagg to identify late gadolinium enhancement was compared using receiver opera

185 farcted versus noninfarcted segments by late gadolinium enhancement was similarly good for regional L

186 age: 40 years) MVP patients without LV late gadolinium enhancement were investigated by morphofuncti

187 uptake, as well as transmural extent of late gadolinium enhancement, acutely can identify viable myoc

188 presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricular e

189 , strain imaging by myocardial tagging, late gadolinium enhancement, and native T1 mapping (Shortened

190 erformed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping.

191 and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared with 14% in HTN subj

192 Heterogeneous gadolinium enhancement, cortical thickness, round shape,

193 Late gadolinium enhancement, however, relies on the regional

194 etic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular fibros

195 a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventricular ejection fracti

196 Late gadolinium enhancement-cardiovascular magnetic resonance

197 In individuals without a late gadolinium enhancement-defined myocardial scar (n = 1131

198 and T2-weighted MR imaging before and after gadolinium enhancement.

199 mapping, rest first pass perfusion, and late gadolinium enhancement.

200 77.8% (14/18) of patients had focal late gadolinium enhancement.

201 terisation with a suggestive pattern of late gadolinium enhancement.

202 ovascular obstruction was assessed with late gadolinium enhancement.

203 nted with cerebral demyelinating lesions and gadolinium enhancement.

204 olic function, native T1 mapping, edema, and gadolinium enhancement.

205 jects in groups 3 and 4 had evidence of late gadolinium enhancement.

206 istribution is not well visualized with late gadolinium enhancement.

207 acterization of replacement fibrosis by late gadolinium enhancement.

208 f 6-month wall thickening compared with late gadolinium enhancement.

209 ortion of total left ventricular mass (%late gadolinium enhancement; 10.4+/-13.2% versus 8.5+/-8.5%;

210 al injury could improve the accuracy of late gadolinium-enhancement in predicting functional recovery

211 ients had brainstem predominant perivascular gadolinium enhancing lesions on magnetic resonance imagi

212 scriminated from non-CLIPPERS by: homogenous gadolinium enhancing nodules <3 mm in diameter without r

213 7 [77%] of 35 participants with no change in gadolinium-enhancing [Gd+] lesion number with opicinumab

214 month 60, mean cumulative numbers of new T2, gadolinium-enhancing and T1 hypointense lesions were low

215 l, IQR = 25.2-65.3) or both brain and spinal gadolinium-enhancing lesions (62.5pg/ml, IQR = 42.7-71.4

216 udy entry to 0.6 at month 24), as well as of gadolinium-enhancing lesions (metformin, 1.8 at study en

217 (OR = 2.36; 95% CI 1.21 to 4.59; p = 0.011), gadolinium-enhancing lesions (OR = 2.69; 95% CI 1.13 to

218 ople with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomo

219 The mean number of gadolinium-enhancing lesions per T1-weighted magnetic re

220 8.4], mean EDSS 4.67 [SD 1.03], 87% free of gadolinium-enhancing lesions).

221 increase in T2 lesion load and the number of gadolinium-enhancing lesions.

222 endpoint was the cumulative number of total gadolinium-enhancing MRI lesions measured by an independ

223 Reductions in mean (95% CI) gadolinium-enhancing T1 lesion counts from the last BOLD

224 ), periventricular T2 lesions (P = 0.580) or gadolinium-enhancing T1 lesions (P = 0.724)].

225 c accuracy of hepato-biliary (HB) phase with gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic a

226 ections of 2.5 mmol gadolinium per kilogram (gadolinium-exposed group) or saline (control group) over

227 nionic iodine-based contrast material, and a gadolinium-filled capsule representing a contrast materi

228 ide accounts for 18.2% +/- 10.6 of the total gadolinium found therein.

229 ith the non-selective cation channel blocker Gadolinium (Gd(3+)).

230 e evaluated both the spatial distribution of gadolinium (Gd) and other rare earth elements (REE) in s

231 resonance (MR) contrast agent with a single gadolinium (Gd) chelate using a quantitative MRI T1 mapp

232 -ray computed tomography (CT) enabled by the gadolinium (Gd) element contained in the UCNP.

233 the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast.

234 he trans-placental permeability of liposomal Gadolinium (Gd) nanoparticle contrast agents was evaluat

235 However, most gadolinium (Gd)-chelator MR contrast agents are limited

236 than some macrocyclic agents, deposition of gadolinium has also been observed with macrocyclic agent

237 In cats and rats, gadolinium has been used to investigate the role played

238 Gadolinium, however, has poor selectivity for mechano-ga

239 Depletion of KC by gadolinium(III) chloride or of LSEC by cyclophosphamide

240 Following the first implementation of gadolinium(III)-based contrast agents in magnetic resona

241 Post-gadolinium imaging was better to assess joint involvemen

242 The mass balance found for gadolinium implies the occurrence of other soluble gadol

243 body elimination, negligible accumulation of gadolinium in bone or tissue, and robust detection of fi

244 e, the clinical significance of the retained gadolinium in the brain, if any, remains unknown.

245 time curve during the first 90 seconds after gadolinium injection [AUGC90], and volume transfer const

246 lar permeability (contrast enhancement after gadolinium injection) were analyzed.

247 VO was assessed 4 and 10 to 15 minutes after gadolinium injection.

248 edict the magnetic coupling between iron and gadolinium layers separated by one to several monolayers

249 were used to assess differences in absolute gadolinium levels and percentage of injected dose, respe

250 Biodistribution showed low tissue gadolinium levels at 24 hours (<3.9% injected dose [ID]/

251 Gadolinium levels were measured by using inductively cou

252 Absolute gadolinium levels were quantified in the blood and brain

253 osition was performed to generate iodine and gadolinium maps.

254 a percentage of injected dose, the levels of gadolinium measured were comparable between different do

255 logic findings associated with the levels of gadolinium measured.

256 of different moieties; Gd3 N@C80 , a kind of gadolinium metallofullerene with three Gd ions in one ca

257 abeled doxorubicin-loaded polydopamine (PDA)-gadolinium-metallofullerene core-satellite nanotheranost

258 Comparing gadolinium MRI (n = 397) with no MRI (n = 1418451), the

259 d 2014 (contrast group) with samples from 10 gadolinium-naive patients who had undergone at least one

260 A peptide-targeted tri-gadolinium nitride metallofullerene, ZD2-Gd3N@C80, is sy

261 T]-diethyneletriaminepentaacetic acid [DTPA]-gadolinium or indium 111-bis-5-HT-DTPA, respectively).

262 , 0.2) in gadoteridol-injected rats, 1.6 mug gadolinium per gram of tissue (95% CI: 0.9, 4.7) in gado

263 9, 4.7) in gadobutrol-injected rats, 4.7 mug gadolinium per gram of tissue (95% CI: 3.5, 6.1) in gado

264 enate dimeglumine-injected rats, and 6.9 mug gadolinium per gram of tissue (95% CI: 6.2, 7.0) in gado

265 .0001), with median concentrations of 0 mug gadolinium per gram of tissue (95% confidence interval [

266 e-exposed patients contained 0.1-19.4 mug of gadolinium per gram of tissue in a statistically signifi

267 ceived 20 intravenous injections of 2.5 mmol gadolinium per kilogram (gadolinium-exposed group) or sa

268 idol, indicating that a very small amount of gadolinium persists after delivery.

269 ling was performed to quantify manganese and gadolinium plasma clearance by using inductively coupled

270 The relaxivity of the gadolinium polysialic acid species formed in vitro was 9

271 Purpose To measure the levels of gadolinium present in the rat brain 1 and 20 weeks after

272 The high atomic number of gadolinium provides a large photoelectric cross-section

273 Purpose To determine whether gadolinium remains in juvenile nonhuman primate tissue a

274 n on days 1, 3, and 7 correlated with the T1-gadolinium results, both of which peaked on day 3.

275 reated with gadodiamide, the largest part of gadolinium retained in brain tissue was insoluble specie

276 gadolinium-based contrast agents (GBCAs) and gadolinium retention in bone.

277 Each subject underwent one measurement of gadolinium retention in the tibia with x-ray fluorescenc

278 Materials and Methods In vivo measurement of gadolinium retention in tibia bones was performed in 11

279 ease of SI in the DN, which is likely due to gadolinium retention.

280 the mechanosensitive ion channel antagonists gadolinium, ruthenium red and D-GsMTx4.

281 Ex-vivo quantification of gadolinium showed significantly higher uptake of EP-3533

282 early differentiated the distributions, with gadolinium solely in the polyp and iodine in the lumen o

283 Gadoteridol comprised 100% of the gadolinium species found in rats treated with gadoterido

284 Post-gadolinium subendocardial hyperenhancement suggested foc

285 rious MRI sequences (T1, T2, STIR, DWI, post-gadolinium T1 FS) were measured and biopsies were obtain

286 ECV was calculated from pre- and post-gadolinium T1 measurements of blood and myocardium, and

287 nsity-lesion length); (iii) optic nerve post-gadolinium T1-weighted (Gd-enhanced lesion length); and

288 CT colonography with iodine-filled lumen and gadolinium-tagged polyps may enable ready differentiatio

289 diodense elements, including iodine, barium, gadolinium, tantalum, ytterbium, gold, and bismuth, were

290 eavy rare earth elements (yttrium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thuliu

291 t5M, where M is lanthanum, cerium, samarium, gadolinium, terbium, dysprosium, thulium, or calcium.

292 Purpose To compare gadolinium tissue concentrations of multiple linear and

293 Relaxometric measurements of gadodiamide and gadolinium trichloride in the presence of polysialic aci

294 Gadolinium was detected in bone up to 5 years after one

295 s far less retained, and the entire detected gadolinium was intact soluble GBCA, while gadodiamide yi

296 Conclusion Tissue deposition of gadolinium was two- to fourfold higher following adminis

297 phase transition in soft magnetic material, gadolinium, was employed to obtain mechanical vibrations

298 Results Dose-dependent low levels of gadolinium were detected in the brain, a mean +/- standa

299 the control group had undetectable levels of gadolinium with ICP-MS.

300 r adults-that is, 100 kVp and higher-barium, gadolinium, ytterbium, and tantalum provided consistentl